Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab

Chordoma, a rare bone tumor derived from the notochord, has been shown to be resistant to conventional therapies. Checkpoint inhibition has shown great promise in immune-mediated therapy of diverse cancers. The anti-PD-L1 mAb avelumab is unique among checkpoint inhibitors in that it is a fully human...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Fujii, Rika, Friedman, Eitan R., Richards, Jacob, Tsang, Kwong Y., Heery, Christopher R., Schlom, Jeffrey, Hodge, James W.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2016
Aiheet:
Priority Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5085098/
https://ncbi.nlm.nih.gov/pubmed/27172898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9256
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia